Pediatric Clinical Trials
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Brentuximab vedotin
Eligibility
Inclusion Criteria:
- Relapsed or refractory CD30-positive malignancy
- Adequate organ function
- ECOG performance status <2
Exclusion Criteria:
- Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)
- Current diagnosis of primary cutaneous ALCL
- Acute or chronic graft-versus-host disease
- Prior hematopoietic stem cell transplant within specified timeframe
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting